He's also not a fan of Biogen Idec (BIIB - commentary - Cramer's Take), and he's short the stock. Biogen has been unable to recover from the massive break in February of last year when Tysabri was pulled off the market. Additionally, he points out that short institutional readings are at a two-year low, indicating a lack of pent-up demand for the shares.
http://www.thestreet.com/_googlen/markets/marketfeatures/10307723.html?cm_ven=GOOGLEN&cm_cat=FREE&cm_ite=NA